Loading Events

« All Events

PARTNER EVENT: AMR Action Summit on R&D and Commercialization

June 10 @ 7:30 am - June 11 @ 5:00 pm

$250 – $350

Visit the Event Website at AMR ACTION SUMMIT
REGISTRATION Early Bird – $250 (until April 30) Regular Rate – $350 (from May 1)

JOIN US in attending this most informative and enlightening event with your executive team and fellow colleagues. The overall objective of the AMR Action Summit is to promote awareness of the global challenge of Antimicrobial resistance and the academic, industry and governmental approaches underway and still required to address this major and growing public health threat.

“Antimicrobial resistance (AMR) is one of the biggest health threats that mankind faces now and in the coming decades. Tackling AMR is absolutely essential. It needs to be seen as the economic and security threat that it is, and be at the forefront of the minds of heads of state, finance ministers, agriculture ministers, and health ministers, for years to come (O’Neill Report, 2016).”

“We have reached a critical point and must act now on a global scale to slow down antimicrobial resistance” – Professor Dame Sally Davies, UK Chief Medical Officer

“If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back into the dark ages of medicine” – David Cameron, former UK Prime Minister


N.C. Biotechnology Center

(Italicized speakers are confirmed, 3/5/19)


Monday, June 10th, 2019


7:00 – 8:15 REGISTRATION/Continental Breakfast

8:15 – 8:20 Welcome, Doug Edgeton, President & CEO, N.C. Biotechnology Center

8:20 – 8:35 Opening Remarks, Victor Dzau, President, National Academy of Medicine

Moderator: Gary Cohen, EVP Global Health, BD & President, BD Foundation

8:40 – 9:10 Topic TBD

9:10 – 9:40 AMR Data and Field Surveillance, CDC, Michael Craig, Senior Advisor for Antibiotic Resistance

9:40 – 10:10 Perspectives from Industry: Relevance of Diagnostics, Christine Ginocchio, VP Global Microbiology Affairs, bioMerieux

10:10 – 10:40 Government of France, TBD (bioMerieux)

10:40 – 11:00 BREAK and NETWORKING

11:00 – 11:45 Panel Discussion and Audience Questions (Moderator: Adam Zerda) Panel: Dame Sally Davies, Michael Craig, Christine Ginocchio, Representative from the Government of France, Tony Fauci)

11:45 – 12:30 Government Policy Statements, Senator Burr (NC), HMA Darroch, Dame Sally Davies

12:30 – 1:30 LUNCH & NETWORKING


1:30 – 1:50 Key Elements to a Successful Public-Private Partnership, Doris Rouse, VP Center for Global Health, RTI International

1:50 – 2:10 CARB-X, Kevin Outterson, Executive Director

2:10 – 2:30 David Payne, VP Infectious Diseases, GlaxoSmithKline (GSK)

2:30 – 2:50 NIAID, Tony Fauci, NIAID Director

2:50 – 3:10 TB Alliance

3:10 – 4:00 Panel Discussion & Audience Questions (Moderator: Doris Rouse; Panel: Kevin Outterson, David Payne, TB Alliance Representative, Tony Fauci, Peter Jackson)

4:00 – 4:30 Putting it All Together, Peter Jackson, Executive Chairman, AMR Centre

4:30 – 4:45 Day 1 Closing Remarks, Andrew Terrell, British Consul to North Carolina and Doug Edgeton

4:45 – 6:00 Networking/Happy Hour

6:00 – 9:00 Dinner at N.C. Biotechnology Center

Tuesday, June 11th, 2019

FUNDING AND COMMERCIALIZATION CHALLENGES – Antibiotic and Diagnostic Development

Moderator: John Rex, MD, Chief Medical Officer & Director, F2G, Ltd

9:00 – 9:05 Welcome & Opening Remarks: John Rex

9:05 – 9:35 Global Economic Challenges in the Fight Against AMR – TBD

9:35 – 9:55 Pull Incentives & Policy Initiatives, Jeremy Knox, Policy Lead-Drug Resistant Infections, Wellcome Trust

9:55 – 10:15 Research, Innovation & Policy Summary, Greg Daniel, Deputy Director and Clinical Professor, Duke Margolis

10:15 – 10:35 BREAK

10:35 – 10:50 Investor’s View, Alan Carr, PhD, Senior Analyst, Needham & Co.

10:50 – 11:05 Allan Coukell, Senior Director, Health Program, The Pew Charitable Trusts

11:05 – 12:25 Roundtable (All, beginning with three company vignettes)

Changing Physician Behavior, Building a Market (bioMerieux)
CEO, UK Product Developer
Funding Story, Paul Garofolo, CEO, Locus Biosciences
Panel Discussion and Audience Questions (Panel: Jeremy Knox, Greg Daniel, Alan Carr, Allan Coukell, bioMerieux, Locus Biosciences, Kevin Outterson, and UK Product Developer)

12:25 – 12:30 Closing Remarks/Call for Action – John Rex


1:20 – 1:30 Welcome & Opening Remarks, Kevin Outterson, Executive Director, CARB-X

1:30 – 1:50 What I wish I knew… Agile Sciences

1:50 – 2:10 AMR disease models relevant for therapeutics, diagnostics and devices, Charles River Labs

2:10 – 2:30 Best Practices for Obtaining Federal Funding, Joe Larsen, StrategicMI

2:30 – 2:50 NIAID Pre-Clinical Development Services: Resources to Facilitate Antibiotic and Diagnostic Development,
Ann Eakin, PhD or Anita Sheoran, PhD

2:50 – 3:10 BREAK

3:10 – 3:30 Intellectual Property Strategies

3:30 – 3:50 Product Developer #1

3:50 – 4:10 Product Developer #2

4:10 – 4:50 Panel Discussion and Audience Questions (Moderator: Kevin Outterson; Panel: Charles River Labs, Joe Larsen, NA, Agile Sciences, NIAID, IP, Product Developers)

4:50 – 5:00 Workshop Closing Remarks, Kevin Outterson

*Italicized speakers are confirmed

Agile Sciences
HM Government
North Carolina Biotechnology Center
RTI International
The Special Event Company
Triangle BABCNC

If you are interested in becoming a sponsor please contact Steve Cain at

Sponsorship Opportunities


June 10 @ 7:30 am
June 11 @ 5:00 pm
$250 – $350
Event Categories:
, ,


Triangle BABCNC
UK Government Office
North Carolina Biotechnology Center


North Carolina Biotechnology Center – Hamner Conference Center
15 T.W. Alexander Drive
RTP, NC 27709-3547 United States
+ Google Map
(919) 541-9366